



Financial Report Fiscal FY03/25

Supplementary Materials

HOGY MEDICAL Co., Ltd.

April 24, 2025

Table of Contents

Consolidated Basis

FY03/25 Statements of Income	1 P
FY03/25 Statements of Income by Quarter	2 P
FY03/26 Projected Statements of Income	3 P
FY03/25 Sales by Product Grouping	4 P
FY03/25 Sales by main Products	5 P
FY03/26 Projected Sales by main products	6 P
SG&A (Actual and Forecast)	7 P
Other Income/Expenses (Actual and Forecast)		
Capital Expenditures and Depreciation Expenses	8 P
Balance Sheets (Major Changes)	9 P
Statements of Cash Flows		

Non-Consolidated Basis

FY03/25 Statements of Income	10 P
FY03/25 Statements of Income by Quarter	11 P
FY03/26 Projected Statements of Income	12 P
Total Manufacturing Costs	13 P

Other

Reference] Sales by main products for the past 10 fiscal years (Consolidated)	14 P
--	-------	------

(Notes Concerning Forward-Looking Statements)

Projections throughout these materials are provided as a reference for investors. They are based on estimates and forecasts, and shall not be regarded as pledges or guarantees. They shall be used on the full acknowledgment that actual results may naturally differ from projections.

FY03/25 Statements of Income (Consolidated)

First Quarter

¥ millions, rounded down,(%)

	June 2024 Results		June 2023 Results		Year-on-Year Comparison	
	Amount	% of total	Amount	% of total	Amount	%
Net sales	9,725	100.0	9,679	100.0	45	100.5
Cost of Sales	6,322	65.0	6,083	62.9	239	103.9
Gross profit	3,402	35.0	3,595	37.1	-193	94.6
SG&A expenses	2,066	21.3	2,293	23.7	-226	90.1
Operating income	1,335	13.7	1,302	13.5	33	102.6
Other income	128		123		5	
Other expenses	58		195		-136	
Ordinary income	1,405	14.5	1,230	12.7	175	114.3
Extraordinary income	-		-		-	
Extraordinary expenses	3		0		2	
Income before income taxes and Corporation tax, etc.	1,402	14.4	1,229	12.7	172	114.0
(Tax burden)	395		347		47	
Minority interests	0		-4		4	
Profit attributable to owners of parent	1,006	10.3	886	9.2	120	113.6
EPS (total shares)	¥39.85		¥35.08			
EPS (minus treasury shares)	¥41.46		¥36.53			
Number of shares outstanding	25,256,963		25,256,963			
Weighted-average number of shares outstanding (after deducting treasury shares)	24,273,849		24,256,963			

First Half

¥ millions, rounded down,(%)

	Sept. 2024 Interim Results		Sept. 2023 Interim Results		Year-on-Year Comparison	
	Amount	% of total	Amount	% of total	Amount	%
Net sales	19,619	100.0	19,536	100.0	82	100.4
Cost of Sales	13,260	67.6	12,597	64.5	662	105.3
Gross profit	6,358	32.4	6,938	35.5	-579	91.6
SG&A expenses	4,275	21.8	4,563	23.4	-287	93.7
Operating income	2,083	10.6	2,375	12.2	-292	87.7
Other income	363		239		124	
Other expenses	410		241		169	
Ordinary income	2,036	10.4	2,373	12.1	-337	85.8
Extraordinary income	1,097		40		1,057	
Extraordinary expenses	532		0		531	
Income before income taxes and minority interests	2,601	13.3	2,413	12.4	188	107.8
Corporation tax, etc.	733		689		44	
(Tax burden)	28.2%		28.6%		0	
Minority interests	0		-8		8	
Profit attributable to owners of parent	1,867	9.5	1,732	8.9	135	107.8
EPS (total shares)	¥82.87		¥68.59			
EPS (minus treasury shares)	¥80.58		¥71.40			
Number of shares outstanding	22,535,463		25,256,963			
Weighted-average number of shares outstanding (after deducting treasury shares)	23,175,606		24,261,879			

Third Quarter

¥ millions, rounded down,(%)

	Dec. 2024 Interim Results		Dec. 2023 Interim Results		Year-on-Year Comparison	
	Amount	% of total	Amount	% of total	Amount	%
Net sales	30,016	100.0	29,754	100.0	262	100.9
Cost of Sales	20,119	67.0	19,423	65.3	696	103.6
Gross profit	9,897	33.0	10,331	34.7	-434	95.8
SG&A expenses	6,491	21.6	6,844	23.0	-353	94.8
Operating income	3,406	11.3	3,487	11.7	-80	97.7
Other income	345		357		-11	
Other expenses	482		256		225	
Ordinary income	3,269	10.9	3,587	12.1	-318	91.1
Extraordinary income	1,097		40		1,057	
Extraordinary expenses	534		10		523	
Income before income taxes and minority interests	3,832	12.8	3,617	12.2	214	105.9
Corporation tax, etc.	1,095		1,019		76	
(Tax burden)	28.6%		28.2%		0	
Minority interests	0		-11		11	
Profit attributable to owners of parent	2,736	9.1	2,609	8.8	127	104.9
EPS (total shares)	¥121.44		¥103.32			
EPS (minus treasury shares)	¥120.90		¥107.54			
Number of shares outstanding	22,535,463		25,256,963			
Weighted-average number of shares outstanding (after deducting treasury shares)	22,635,124		24,266,016			

Full-year

¥ millions, rounded down,(%)

	Mar. 2025 Results		Mar. 2024 Results		Year-on-Year Comparison		Mar. 2025 Initial Plan		Revised Plan Comparison	
	Amount	% of total	Amount	% of total	Amount	%	Amount	% of total	Amount	%
Net sales	39,138	100.0	39,100	100.0	37	100.1	40,850	100.0	-1,711	95.8
Cost of Sales	26,517	67.8	26,037	66.6	480	101.8	26,780	65.6	-262	99.0
Gross profit	12,621	32.2	13,063	33.4	-442	96.6	14,070	34.4	-1,448	89.7
SG&A expenses	8,810	22.5	8,894	22.7	-84	99.1	9,380	23.0	-569	93.9
Operating income	3,810	9.7	4,169	10.7	-358	91.4	4,690	11.5	-879	81.3
Other income	457		440		16		260		197	
Other expenses	622		363		258		150		472	
Ordinary income	3,645	9.3	4,245	10.9	-600	85.9	4,800	11.8	-1,154	75.9
Extraordinary income	1,109		40		-		-		1,109	
Extraordinary expenses	1,820		210		-		-		1,820	
Income before income taxes and minority interests	2,934	7.5	4,075	10.4	-1,141	72.0	4,800	11.8	-1,865	61.1
Corporation tax, etc.	1,413		1,282		131		1,490		-76	
(Tax burden)	48.2%		31.5%		0		31.0%			
Minority interests	0		-11		11		-		0	
Profit attributable to owners of parent	1,520	3.9	2,804	7.2	-1,283	54.2	3,310	8.1	-1,789	45.9
EPS (total shares)	¥67.48		¥111.04				¥146.88			
EPS (minus treasury shares)	¥67.98		¥115.57				¥147.97			
Number of shares outstanding	22,535,463		25,256,963				22,535,463			
Weighted-average number of shares outstanding (after deducting treasury shares)	22,370,003		24,268,040				22,370,003			

FY03/25 Statements of Income by Quarter (Consolidated)

FY03/25 Results

¥ millions, rounded down

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Half	Third Quarter (Cumulative)	Full-year
Net sales	9,725	9,893	10,397	9,121	19,619	30,016	39,138
Cost of Sales	6,322	6,937	6,859	6,397	13,260	20,119	26,517
Gross profit	3,402	2,956	3,538	2,723	6,358	9,897	12,621
SG&A expenses	2,066	2,208	2,216	2,318	4,275	6,491	8,810
Operating income	1,335	747	1,322	404	2,083	3,406	3,810
Other income	128	234	-17	111	363	345	457
Other expenses	58	351	71	140	410	482	622
Ordinary income	1,405	630	1,233	376	2,036	3,269	3,645
Extraordinary income	-	1,097	-	12	1,097	1,097	1,109
Extraordinary expenses	3	529	2	1,285	532	534	1,820
Income before income taxes and minority interests	1,402	1,199	1,230	-897	2,601	3,832	2,934
Corporation tax, etc.	395	338	361	318	733	1,095	1,413
(Tax burden)	28.2%	28.2%	29.4%	-35.4%	28.2%	28.6%	48.2%
Minority interests	0	0	0	0	0	0	0
Profit attributable to owners of parent	1,006	860	869	-1,215	1,867	2,736	1,520

FY03/24 Results

¥ millions, rounded down

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Half	Third Quarter (Cumulative)	Full-year
Net sales	9,679	9,856	10,218	9,345	19,536	29,754	39,100
Cost of Sales	6,083	6,513	6,825	6,613	12,597	19,423	26,037
Gross profit	3,595	3,343	3,392	2,731	6,938	10,331	13,063
SG&A expenses	2,293	2,269	2,281	2,049	4,563	6,844	8,894
Operating income	1,302	1,073	1,111	682	2,375	3,487	4,169
Other income	123	116	118	82	239	357	440
Other expenses	195	46	15	107	241	256	363
Ordinary income	1,230	1,143	1,214	657	2,373	3,587	4,245
Extraordinary income	-	40	-	-	40	40	40
Extraordinary expenses	0	0	9	199	0	10	210
Income before income taxes and minority interests	1,229	1,183	1,204	458	2,413	3,617	4,075
Corporation tax, etc.	347	341	330	263	689	1,019	1,282
(Tax burden)	28.3%	28.8%	27.4%	57.4%	28.6%	28.2%	31.5%
Minority interests	-4	-3	-3	0	-8	-11	-11
Profit attributable to owners of parent	886	846	877	195	1,732	2,609	2,804

Change(Amount)

¥ millions, rounded down

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Half	Third Quarter (Cumulative)	Full-year
Net sales	45	36	179	-224	82	262	37
Cost of Sales	239	423	33	-215	662	696	480
Gross profit	-193	-386	145	-8	-579	-434	-442
SG&A expenses	-226	-61	-65	268	-287	-353	-84
Operating income	33	-325	211	-277	-292	-80	-358
Other income	5	118	-135	28	124	-11	16
Other expenses	-136	305	56	33	169	225	258
Ordinary income	175	-512	18	-281	-337	-318	-600
Extraordinary income	-	1,057	-	12	1,057	1,057	1,069
Extraordinary expenses	2	528	-7	1,086	531	523	1,610
Income before income taxes and minority interests	172	15	26	-1,355	188	214	-1,141
Corporation tax, etc.	47	-3	31	54	44	76	131
(Tax burden)							
Minority interests	4	3	3	0	8	11	11
Profit attributable to owners of parent	120	14	-8	-1,410	135	127	-1,283

Change

(%)

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Half	Third Quarter (Cumulative)	Full-year
Net sales	100.5	100.4	101.8	97.6	100.4	100.9	100.1
Cost of Sales	103.9	106.5	100.5	96.7	105.3	103.6	101.8
Gross profit	94.6	88.4	104.3	99.7	91.6	95.8	96.6
SG&A expenses	90.1	97.3	97.1	113.1	93.7	94.8	99.1
Operating income	102.6	69.7	119.0	59.3	87.7	97.7	91.4
Other income							
Other expenses							
Ordinary income	114.3	55.1	101.6	57.2	85.8	91.1	85.9
Extraordinary income							
Extraordinary expenses							
Income before income taxes and minority interests	114.0	101.3	102.2	-196.0	107.8	105.9	72.0
Corporation tax, etc.							
(Tax burden)							
Minority interests							
Profit attributable to owners of parent	113.6	101.7	99.1	-623.5	107.8	104.9	54.2

Breakdown

(%)

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Half	Third Quarter (Cumulative)	Full-year
Net sales	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Cost of Sales	65.0	70.1	66.0	70.1	67.6	67.0	67.8
Gross profit	35.0	29.9	34.0	29.9	32.4	33.0	32.2
SG&A expenses	21.3	22.3	21.3	25.4	21.8	21.6	22.5
Operating income	13.7	7.6	12.7	4.4	10.6	11.3	9.7
Other income							
Other expenses							
Ordinary income	14.5	6.4	11.9	4.1	10.4	10.9	9.3
Extraordinary income							
Extraordinary expenses							
Income before income taxes and minority interests	14.4	12.1	11.8	-9.8	13.3	12.8	7.5
Corporation tax, etc.							
(Tax burden)							
Minority interests							
Profit attributable to owners of parent	10.3	8.7	8.4	-13.3	9.5	9.1	3.9

FY03/26 Projected Statements of Income (Consolidated)

Cumulative

¥ millions, rounded down

	First Half	% of total	Full-year	% of total
Net sales	20,170	100.0	41,790	100.0
Operating income	1,840	9.1	4,300	10.3
Ordinary income	1,900	9.4	4,430	10.6
Profit attributable to owners of parent	1,300	6.4	3,020	7.2

EPS (before deducting treasury shares)

¥57.69

¥134.01

EPS (minus treasury shares)

¥60.30

¥140.08

Number of shares outstanding

22,535,463

Shares outstanding at FY03/25 year-end

21,559,832

(deducting treasury shares)

FY03/25 Results

¥ millions, rounded down,(%)

Net sales	19,619	100.0	39,138	100.0
Operating income	2,083	10.6	3,810	9.7
Ordinary income	2,036	10.4	3,645	9.3
Profit attributable to owners of parent	1,867	9.5	1,520	3.9

Change (Amount and %)

Net sales	550	102.8	2,651	106.8
Operating income	-243	88.3	489	112.8
Ordinary income	-136	93.3	784	121.5
Profit attributable to owners of parent	-567	69.6	1,499	198.6

FY03/25 Sales by Product Grouping (Consolidated)

First Half

¥ millions, rounded down,(%)

	Sept. 2024 Interim Results		Sept. 2023 Interim Results		Year-on-Year Comparison	
	Amount	% of total	Amount	% of total	Amount	%
Sterilization products	1,695	8.6	1,673	8.6	21	101.3
Surgical products	17,452	89.0	17,394	89.0	57	100.3
Treatment products	89	0.5	86	0.4	2	103.3
Others	382	1.9	381	2.0	0	100.1
Total	19,619	100.0	19,536	100.0	82	100.4

Itemized surgical products

Non-woven products	3,614	18.4	3,793	19.4	-178	95.3
Other non-woven products	670	3.4	788	4.0	-118	85.0
Kit products	12,992	66.2	12,701	65.0	290	102.3
New products	176	0.9	112	0.6	63	157.0

Itemized external sales by subsidiary

Non-woven products	235		235		-0	
Other non-woven products	1		-		1	
Kit products	27		24		3	
Others	41		34		6	

Third Quarter

¥ millions, rounded down,(%)

	Dec. 2024 Interim Results		Dec. 2023 Interim Results		Year-on-Year Comparison	
	Amount	% of total	Amount	% of total	Amount	%
Sterilization products	2,588	8.6	2,579	8.7	8	100.3
Surgical products	26,713	89.0	26,459	88.9	254	101.0
Treatment products	133	0.4	131	0.4	2	101.7
Others	580	1.9	583	2.0	-3	99.5
Total	30,016	100.0	29,754	100.0	262	100.9

Itemized surgical products

Non-woven products	5,463	18.2	5,757	19.3	-294	94.9
Other non-woven products	1,008	3.4	1,146	3.9	-138	87.9
Kit products	19,994	66.6	19,374	65.1	620	103.2
New products	247	0.8	181	0.6	66	136.6

Itemized external sales by subsidiary

Non-woven products	317		368		-50	
Other non-woven products	1		1		-0	
Kit products	41		47		-5	
Others	52		55		-2	

Full-year

¥ millions, rounded down,(%)

	Mar. 2025 Results		Mar. 2024 Results		Year-on-Year Comparison		Mar. 2025 Initial Plan		Revised Plan Comparison	
	Amount	% of total	Amount	% of total	Amount	%	Amount	% of total	Amount	%
Sterilization products	3,410	8.7	3,439	8.8	-29	99.2	3,442	8.4	-31	99.1
Surgical products	34,777	88.9	34,725	88.8	51	100.1	36,436	89.2	-1,658	95.4
Treatment products	172	0.4	173	0.4	-1	99.4	212	0.5	-39	81.5
Others	778	2.0	761	1.9	16	102.2	760	1.9	18	102.4
Total	39,138	100.0	39,100	100.0	37	100.1	40,850	100.0	-1,711	95.8




Itemized surgical products

Non-woven products	7,124	18.2	7,452	19.1	-327	95.6	7,134	17.5	-9	99.9
Other non-woven products	1,301	3.3	1,503	3.8	-201	86.6	1,429	3.5	-127	91.1
Kit products	26,018	66.5	25,503	65.2	515	102.0	27,438	67.2	-1,419	94.8
New products	332	0.8	266	0.7	65	124.7	434	1.1	-101	76.6

Itemized external sales by subsidiary

Non-woven products	483		443		39		415		68	
Other non-woven products	1		1		0		1		-0	
Kit products	79		55		23		64		15	
Others	77		66		11		70		7	

Sales Composition by Kit Treatment Category



FY03/25 Sales by main Products (Consolidated)

This document is a new document from FY2024. Please refer to page 14 for the results of the past 10 fiscal years.

First Half

¥ millions, rounded down,(%)

	Sept. 2024 Interim Results		Sept. 2023 Interim Results		Year-on-Year Comparison	
	Amount	% of total	Amount	% of total	Amount	% of total
Kit products	12,992	66.2	12,701	65.0	290	102.3
Non-woven products	3,614	18.4	3,793	19.4	-178	95.3
Mekkin bag	1,238	6.3	1,246	6.4	-7	99.4
Other non-woven products	670	3.4	788	4.0	-118	85.0
New products	184	0.9	113	0.6	70	162.0
Others	877	4.5	859	4.4	18	102.2
Subsidiaries & other sales	41	0.2	34	0.2	6	120.2
Total	19,619	100.0	19,536	100.0	82	100.4

Itemized external sales by subsidiary

Kit products	27	24	3
Non-woven products	235	235	-0
Other non-woven products	1	-	1
Others	41	34	6

Third Quarter

¥ millions, rounded down,(%)

	Dec. 2024 Interim Results		Dec. 2023 Interim Results		Year-on-Year Comparison	
	Amount	% of total	Amount	% of total	Amount	% of total
Kit products	19,994	66.6	19,374	65.1	620	103.2
Non-woven products	5,463	18.2	5,757	19.3	-294	94.9
Mekkin bag	1,908	6.4	1,929	6.5	-20	98.9
Other non-woven products	1,008	3.4	1,146	3.9	-138	87.9
New products	258	0.9	185	0.6	73	139.7
Others	1,329	4.4	1,306	4.4	23	101.8
Subsidiaries & other sales	52	0.2	55	0.2	-2	95.2
Total	30,016	100.0	29,754	100.0	262	100.9

Itemized external sales by subsidiary

Kit products	41	47	-5
Non-woven products	317	368	-50
Other non-woven products	1	1	-0
Others	52	55	-2

Full-year

¥ millions, rounded down,(%)

	Mar. 2025 Results		Mar. 2024 Results		Year-on-Year Comparison		Mar. 2025 Initial Plan		Revised Plan Comparison	
	Amount	% of total	Amount	% of total	Amount	%	Amount	% of total	Amount	%
Kit products	26,018	66.5	25,503	65.2	515	102.0	27,438	67.2	-1,419	94.8
Non-woven products	7,124	18.2	7,452	19.1	-327	95.6	7,134	17.5	-9	99.9
Mekkin bag	2,519	6.4	2,538	6.5	-18	99.3	2,538	6.2	-18	99.3
Other non-woven products	1,301	3.3	1,503	3.8	-201	86.6	1,429	3.5	-128	91.0
New products	345	0.9	274	0.7	70	125.7	480	1.2	-134	72.0
Others	1,750	4.5	1,761	4.5	-11	99.4	1,760	4.3	-9	99.5
Subsidiaries & other sales	77	0.2	66	0.2	11	116.9	70	0.2	7	111.0
Total	39,138	100.0	39,100	100.0	37	100.1	40,850	100.0	-1,711	95.8

Itemized external sales by subsidiary

Kit products	79	55	23	64	15
Non-woven products	483	443	39	415	68
Other non-woven products	1	1	0	1	-0
Others	77	66	11	70	7

FY03/26 Projected Sales by main products (Consolidated)

¥ millions, rounded down

	First Half	Full-year
Kit products	13,835	28,802
Non-woven products	3,435	6,974
Mekkin bag	1,200	2,450
Other non-woven products	613	1,263
New products	196	491
Others	854	1,736
Subsidiaries & other sales	37	74
Total	20,170	41,790

Itemized external sales by subsidiary

Kit products	44	175
Non-woven products	234	512
Other non-woven products	-	-
Others	37	74

¥ millions, rounded down

(Change(Amount))	First Half	Full-year
Kit products	842	2,783
Non-woven products	-179	-150
Mekkin bag	-38	-69
Other non-woven products	-57	-38
New products	11	145
Others	-23	-14
Subsidiaries & other sales	-4	-3
Total	550	2,651

Itemized external sales by subsidiary

Kit products	16	96
Non-woven products	-0	29
Other non-woven products	-1	-1
Others	-4	-3

(%)

(Breakdown)	First Half	Full-year
Kit products	68.6	68.9
Non-woven products	17.0	16.7
Mekkin bag	5.9	5.9
Other non-woven products	3.0	3.0
New products	1.0	1.2
Others	4.2	4.2
Subsidiaries & other sales	0.2	0.2
Total	100.0	100.0

Itemized external sales by subsidiary

Kit products	0.2	0.4
Non-woven products	1.2	1.2
Other non-woven products	0.0	0.0
Others	0.2	0.2

¥ millions, rounded down

(FY03/25 Results)	First Half	Full-year
Kit products	12,992	26,018
Non-woven products	3,614	7,124
Mekkin bag	1,238	2,519
Other non-woven products	670	1,301
New products	184	345
Others	877	1,750
Subsidiaries & other sales	41	77
Total	19,619	39,138

Itemized external sales by subsidiary

Kit products	27	79
Non-woven products	235	483
Other non-woven products	1	1
Others	41	77

(%)

(Change)	First Half	Full-year
Kit products	106.5	110.7
Non-woven products	95.0	97.9
Mekkin bag	96.9	97.2
Other non-woven products	91.5	97.0
New products	106.1	142.1
Others	97.3	99.2
Subsidiaries & other sales	89.7	95.3
Total	102.8	106.8

Itemized external sales by subsidiary

Kit products	158.5	221.5
Non-woven products	99.8	106.0
Other non-woven products	0.0	0.0
Others	89.7	95.0

SG&A (Actual and Forecast)Other Income/Expenses (Actual and Forecast)
SG&A Expenses

¥ millions, rounded down

	FY03/25 Results	FY03/24 Results	Year-on-Year Comparison	FY03/26 Initial Plan	Initial Plan Comparison
Packaging and transportation	1,120	1,089	31	1,210	89
Losses on doubtful accounts	-	-	-	-	-
Samples	301	375	-73	305	4
Advertising	75	61	13	186	111
Personnel	3,742	4,008	-266	4,115	373
Travel	457	437	20	524	67
Communication	135	142	-7	141	5
Consumables	61	47	14	54	-7
Taxes and public charges	319	312	6	300	-18
Depreciation	522	572	-50	575	53
Testing and research	282	220	61	530	248
Land and housing rent	444	438	6	476	31
Miscellaneous	647	544	102	893	246
Others	700	643	56	984	284
Total	8,810	8,894	-84	10,300	1,489

Other Income/Expenses

¥ millions, rounded down

	FY03/25 Results	FY03/24 Results	Year-on-Year Comparison	FY03/26 Initial Plan	Initial Plan Comparison
Interest received	214	249	-35	203	-11
Interest on negotiable securities	-	-	-	-	-
Dividend received	71	58	12	59	-11
(Total financial earnings)	285	307	-22	262	-22
Foreign exchange gain	33	-	33	-	-33
Miscellaneous income	138	132	5	27	-110
Total Other income	457	440	16	290	-167
Paid interest	70	23	47	109	38
(Total financial expenses)	70	23	47	109	38
Foreign exchange loss	-	37	-37	-	-
Miscellaneous losses	552	303	248	50	-501
Total non-operating expenses	622	363	258	160	-462

Capital Expenditures and Depreciation Expenses (Actual and Forecast, Consolidated)

Capital Expenditures

	Capital Expenditures	Year-on-Year Comparison
FY03/14	7,174	374.6
FY03/15	15,082	210.2
FY03/16	9,080	60.2
FY03/17	6,649	73.2
FY03/18	2,142	32.2
FY03/19	3,364	157.0
FY03/20	10,904	324.1
FY03/21	5,261	48.2
FY03/22	3,489	66.3
FY03/23	1,458	41.8
FY03/24	1,249	85.7
FY03/25	5,642	451.7
FY03/26	5,280	93.6

Depreciation Expenses

¥ millions, rounded down,(%)

	SG&A Expenses	Year-on-Year Comparison	Manufacturing Costs	Year-on-Year Comparison	Total Depreciation Expenses	Total Depreciation Expenses
FY03/14	922	109.2	1,942	91.3	2,865	96.4
FY03/15	951	103.1	1,757	90.5	2,708	94.5
FY03/16	1,044	109.8	2,331	132.7	3,376	124.7
FY03/17	1,007	96.5	3,402	145.9	4,409	130.6
FY03/18	914	90.8	5,320	156.4	6,235	141.4
FY03/19	998	109.2	4,632	87.1	5,631	90.3
FY03/20	1,070	107.2	4,212	90.9	5,283	93.8
FY03/21	906	84.7	3,643	86.5	4,549	86.1
FY03/22	805	88.9	3,309	90.8	4,115	90.5
FY03/23	669	83.1	2,966	89.6	3,635	88.3
FY03/24	572	85.5	6,034	203.4	6,607	181.8
FY03/25	522	91.3	5,219	86.5	5,741	86.9
FY03/26	580	111.1	4,900	93.9	5,480	95.5

Note: Figures for 03/26 are Company forecasts.

FY03/06 Operamaster expansion line : 1,469, New distribution center : 1,947
FY03/07 New distribution center : 886
FY03/08 Industrial-use land : 973
FY03/09 Industrial-use land : 752, Sterilization equipment : 876 ,Indonesia factory : 381
FY03/10 Sterilization equipment : 1,833 ,Indonesia factory : 995
FY03/11 Sterilization equipment : 2,732
FY03/14 New plant construction costs : 5,166
FY03/15 New plant construction costs : 8,113, New plant equipment costs : 4,567
FY03/16 New plant : 7,300
FY03/17 New plant : 5,981
FY03/20 New plant additional investment : 9,512
FY03/21 New plant additional investment : 3,644
FY03/22 New plant additional investment : 1,830
FY03/25 Indonesia factory : 2,691

Balance Sheets (Major Changes)/Statements of Cash Flows (Consolidated)

Major Changes on Balance Sheets

¥ millions, rounded down

	Balance at March. 31, 2025	Change		Balance at March. 31, 2025	Change
Current assets	44,200	1,174	Current liabilities	10,381	2,140
Cash and bank deposits	22,005	2,586	Notes and accounts payable	4,765	-69
Notes and accounts receivable	11,446	-1,320	Accrued expenses	465	333
Short-term investments	-	-	Long-term loans due within 1 year	1,999	-
Inventories	9,945	488	Income taxes	1,041	939
Others	803	-578	Allowance for employees' bonuses	528	-5
			Payable notes for equipment	120	-35
			Reserve for disaster loss	-	-
			Others	1,461	978
Fixed assets	53,694	-3,321	Long-term liabilities	13,180	7,500
Property, plant and equipment	45,763	50	Long-term borrowings	11,670	8,000
Buildings and structures	21,550	2,016	Others	1,510	-500
Machinery, equipment and vehicles	11,736	-2,989	Total liabilities	23,562	9,640
Land	9,793	64	Total net assets	74,332	-11,787
Construction in progress	2,226	984	Common stock	7,123	-
Others	456	-24	Capital surplus	8,294	-
Intangibles	377	-118	Retained earnings	56,552	-11,210
Investments and others	7,554	-3,253	Treasury stock	-3,909	-692
Investments securities	5,982	-3,230	Others	6,272	115
Others	1,571	-22			
Total assets	97,895	-2,146	Total liabilities and shareholders' equity	97,895	-2,146

*Comparison with end of previous fiscal year:

Equity ratio increased from 86.1% at the end of the previous fiscal year to 75.9%.

Statements of Cash Flows

¥ millions, rounded down

I Operating activities	11,555	Income before income taxes	2,934
		Depreciation	5,741
		Incomes taxes paid	-1,109
II Investing activities	-3,917	Purchase of tangible fixed assets	-5,230
III Financing activities	-5,455	Proceeds from long-term borrowings	10,000
		Purchase of treasury stock	-11,623
IV Effect of exchange rate changes	528		
Net changes in cash and cash equivalents	2,710		

FY03/25 Statements of Income (Non-Consolidated)

First Quarter

¥ millions, rounded down,(%)

	June 2024 Results		June 2023 Results		Year-on-Year Comparison	
	Amount	% of total	Amount	% of total	Amount	%
Net sales	9,578	100.0	9,564	100.0	14	100.2
Cost of Sales	6,413	67.0	6,132	64.1	280	104.6
Gross profit	3,165	33.0	3,431	35.9	-266	92.2
SG&A expenses	2,006	21.0	2,232	23.3	-226	89.9
Operating income	1,158	12.1	1,198	12.5	-39	96.7
Other income	91		65		25	
Other expenses	106		199		-93	
Ordinary income	1,143	11.9	1,064	11.1	78	107.4
Extraordinary income	-		-		-	
Extraordinary expenses	3		0		2	
Income before income taxes	1,140	11.9	1,064	11.1	75	107.1
Corporation tax, etc.	347		320		27	
(Tax burden)	30.5%		30.1%		0	
Net income	792	8.3	743	7.8	48	106.5

EPS (total shares)

¥31.37

¥29.45

EPS (minus treasury shares)

¥32.64

¥30.67

Number of shares outstanding

25,256,963

25,256,963

Weighted-average number of shares outstanding

(after deducting treasury shares)

24,273,849

24,256,963

First Half

¥ millions, rounded down,(%)

	Sept. 2024 Interim Results		Sept. 2023 Interim Results		Year-on-Year Comparison	
	Amount	% of total	Amount	% of total	Amount	%
Net sales	19,325	100.0	19,263	100.0	62	100.3
Cost of Sales	13,354	69.1	12,678	65.8	676	105.3
Gross profit	5,971	30.9	6,585	34.2	-613	90.7
SG&A expenses	4,151	21.5	4,428	23.0	-277	93.7
Operating income	1,820	9.4	2,156	11.2	-336	84.4
Other income	234		146		87	
Other expenses	459		272		186	
Ordinary income	1,594	8.3	2,030	10.5	-435	78.5
Extraordinary income	1,097		40		1,057	
Extraordinary expenses	532		0		531	
Income before income taxes	2,160	11.2	2,070	10.7	89	104.3
Corporation tax, etc.	659		623		35	
(Tax burden)	30.5%		30.1%		0	
Net income	1,501	7.8	1,446	7.5	54	103.7

EPS (total shares)

¥66.61

¥57.28

EPS (minus treasury shares)

¥64.77

¥59.63

Number of shares outstanding

22,535,463

25,256,963

Weighted-average number of shares outstanding

(after deducting treasury shares)

23,175,606

24,261,879

Third Quarter

¥ millions, rounded down,(%)

	Dec. 2024 Interim Results		Dec. 2023 Interim Results		Year-on-Year Comparison	
	Amount	% of total	Amount	% of total	Amount	%
Net sales	29,631	100.0	29,309	100.0	322	101.1
Cost of Sales	20,315	68.6	19,592	66.8	722	103.7
Gross profit	9,315	31.4	9,716	33.2	-400	95.9
SG&A expenses	6,323	21.3	6,632	22.6	-309	95.3
Operating income	2,992	10.1	3,084	10.5	-91	97.0
Other income	232		208		23	
Other expenses	545		323		221	
Ordinary income	2,680	9.0	2,969	10.1	-289	90.3
Extraordinary income	1,097		40		1,057	
Extraordinary expenses	533		0		532	
Income before income taxes	3,244	10.9	3,009	10.3	235	107.8
Corporation tax, etc.	989		906		83	
(Tax burden)	30.5%		30.1%		0	
Net income	2,254	7.6	2,103	7.2	151	107.2

EPS (total shares)

¥100.05

¥83.28

EPS (minus treasury shares)

¥99.61

¥86.68

Number of shares outstanding

22,535,463

25,256,963

Weighted-average number of shares outstanding

(after deducting treasury shares)

22,635,124

24,266,016

Full-year

¥ millions, rounded down,(%)

	Mar. 2025 Results		Mar. 2024 Results		Year-on-Year Comparison		Mar. 2025 Initial Plan		Revised Plan Comparison	
	Amount	% of total	Amount	% of total	Amount	%	Amount	% of total	Amount	%
Net sales	38,531	100.0	38,569	100.0	-38	99.9	40,350	100.0	-1,818	95.5
Cost of Sales	26,744	69.4	26,270	68.1	474	101.8	27,160	67.3	-415	98.5
Gross profit	11,786	30.6	12,298	31.9	-512	95.8	13,190	32.7	-1,403	89.4
SG&A expenses	8,554	22.2	8,621	22.4	-67	99.2	9,130	22.6	-575	93.7
Operating income	3,231	8.4	3,676	9.5	-445	87.9	4,060	10.1	-828	79.6
Other income	446		533		-87		450		-3	
Other expenses	691		439		252		200		491	
Ordinary income	2,986	7.7	3,771	9.8	-785	79.2	4,310	10.7	-1,323	69.3
Extraordinary income	1,109		40		1,069		-		1,109	
Extraordinary expenses	1,819		770		1,048		-		1,819	
Income before income taxes	2,276	5.9	3,041	7.9	-764	74.9	4,310	10.7	-2,033	52.8
Corporation tax, etc.	1,400		943		456		1,290		110	
(Tax burden)	61.5%		31.0%		0		29.9%		0	
Net income	876	2.3	2,097	5.4	-1,221	41.8	3,020	7.5	-2,143	29.0

EPS (total shares)

¥38.90

¥83.06

¥134.01

EPS (minus treasury shares)

¥39.18

¥86.44

¥135.00

Number of shares outstanding

22,535,463

25,256,963

22,535,463

Weighted-average number of shares outstanding

(after deducting treasury shares)

22,370,003

24,268,040

22,370,003

FY03/25 Statements of Income by Quarter (Non-Consolidated)

FY03/25 Results

¥ millions, rounded down

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Half	Third Quarter (Cumulative)	Full-year
Net sales	9,578	9,747	10,305	8,899	19,325	29,631	38,531
Cost of Sales	6,413	6,940	6,961	6,429	13,354	20,315	26,744
Gross profit	3,165	2,806	3,344	2,470	5,971	9,315	11,786
SG&A expenses	2,006	2,144	2,172	2,231	4,151	6,323	8,554
Operating income	1,158	661	1,172	238	1,820	2,992	3,231
Other income	91	143	-1	213	234	232	446
Other expenses	106	353	85	146	459	545	691
Ordinary income	1,143	451	1,085	305	1,594	2,680	2,986
Extraordinary income	-	1,097	-	12	1,097	1,097	1,109
Extraordinary expenses	3	529	1	1,285	532	533	1,819
Income before income taxes	1,140	1,020	1,084	-967	2,160	3,244	2,276
Corporation tax, etc.	347	311	330	410	659	989	1,400
(Tax burden)	30.5%	30.5%	30.5%	-42.4%	30.5%	30.5%	61.5%
Net income	792	708	753	-1,378	1,501	2,254	876

FY03/24 Results

¥ millions, rounded down

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Half	Third Quarter (Cumulative)	Full-year
Net sales	9,564	9,699	10,045	9,260	19,263	29,309	38,569
Cost of Sales	6,132	6,545	6,914	6,678	12,678	19,592	26,270
Gross profit	3,431	3,154	3,131	2,582	6,585	9,716	12,298
SG&A expenses	2,232	2,195	2,203	1,989	4,428	6,632	8,621
Operating income	1,198	958	927	592	2,156	3,084	3,676
Other income	65	81	62	324	146	208	533
Other expenses	199	73	50	116	272	323	439
Ordinary income	1,064	965	939	801	2,030	2,969	3,771
Extraordinary income	-	40	-	-	40	40	40
Extraordinary expenses	0	0	0	769	0	0	770
Income before income taxes	1,064	1,005	939	31	2,070	3,009	3,041
Corporation tax, etc.	320	302	282	37	623	906	943
(Tax burden)	30.1%	30.1%	30.1%	117.7%	30.1%	30.1%	31.0%
Net income	743	702	656	-5	1,446	2,103	2,097

Change(Amount)

¥ millions, rounded down

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Half	Third Quarter (Cumulative)	Full-year
Net sales	14	47	259	-360	62	322	-38
Cost of Sales	280	395	46	-248	676	722	474
Gross profit	-266	-347	213	-111	-613	-400	-512
SG&A expenses	-226	-51	-31	242	-277	-309	-67
Operating income	-39	-296	244	-354	-336	-91	-445
Other income	25	62	-63	-110	87	23	-87
Other expenses	-93	279	34	30	186	221	252
Ordinary income	78	-514	146	-495	-435	-289	-785
Extraordinary income	-	1,057	-	12	1,057	1,057	1,069
Extraordinary expenses	2	528	1	515	531	532	1,048
Income before income taxes	75	14	145	-999	89	235	-764
Corporation tax, etc.	27	8	48	373	35	83	456
(Tax burden)							
Net income	48	5	97	-1,372	54	151	-1,221

Change

(%)

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Half	Third Quarter (Cumulative)	Full-year
Net sales	100.2	100.5	102.6	96.1	100.3	101.1	99.9
Cost of Sales	104.6	106.0	100.7	96.3	105.3	103.7	101.8
Gross profit	92.2	89.0	106.8	95.7	90.7	95.9	95.8
SG&A expenses	89.9	97.7	98.6	112.2	93.7	95.3	99.2
Operating income	96.7	69.1	126.4	40.3	84.4	97.0	87.9
Other income							
Other expenses							
Ordinary income	107.4	46.7	115.6	38.2	78.5	90.3	79.2
Extraordinary income							
Extraordinary expenses							
Income before income taxes	107.1	101.4	115.4	-3063.0	104.3	107.8	74.9
Corporation tax, etc.							
(Tax burden)							
Net income	106.5	100.8	114.8	24691.8	103.7	107.2	41.8

Breakdown

(%)

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	First Half	Third Quarter (Cumulative)	Full-year
Net sales	100.0	100.0	100.0	100.0	100.0	100.0	100.0
Cost of Sales	67.0	71.2	67.5	72.2	69.1	68.6	69.4
Gross profit	33.0	28.8	32.5	27.8	30.9	31.4	30.6
SG&A expenses	21.0	22.0	21.1	25.1	21.5	21.3	22.2
Operating income	12.1	6.8	11.4	2.7	9.4	10.1	8.4
Other income							
Other expenses							
Ordinary income	11.9	4.6	10.5	3.4	8.3	9.0	7.7
Extraordinary income							
Extraordinary expenses							
Income before income taxes	11.9	10.5	10.5	-10.9	11.2	10.9	5.9
Corporation tax, etc.							
(Tax burden)							
Net income	8.3	7.3	7.3	-15.5	7.8	7.6	2.3

FY03/26 Projected Statements of Income (Non-Consolidated)

Cumulative

¥ millions, rounded down,(%)

	First Half	% of total	Full-year	% of total
Net sales	19,880	100.0	41,140	100.0
Operating income	1,740	8.8	3,700	9.0
Ordinary income	1,710	8.6	3,900	9.5
Net income	1,200	6.0	2,720	6.6

EPS (before deducting treasury shares) ¥53.25 ¥120.70

EPS (minus treasury shares) ¥55.66 ¥126.16

Number of shares outstanding 22,535,463

Shares outstanding at FY03/25 year-end 21,559,832

(deducting treasury shares)

FY03/25 Results

¥ millions, rounded down,(%)

Net sales	19,325	100.0	38,531	100.0
Operating income	1,820	9.4	3,231	8.4
Ordinary income	1,594	8.3	2,986	7.7
Net income	1,501	7.8	876	2.3

Change (Amount and %)

Net sales	554	102.9	2,608	106.8
Operating income	-80	95.6	468	114.5
Ordinary income	115	107.2	913	130.6
Net income	-301	79.9	1,843	310.3

Manufacturing Costs (Non-consolidated)

¥ millions, rounded down

	FY03/16	FY03/17	FY03/18	FY03/19	FY03/20	FY03/21	FY03/22	FY03/23	FY03/24	FY03/25	Plan FY03/26
Materials	12,545	12,945	12,803	12,769	12,765	12,883	12,287	13,870	15,030	15,441	16,325
Personnel	1,795	1,742	1,713	1,661	1,658	1,750	1,748	1,853	1,958	2,035	2,073
Outsourcing	406	411	398	412	369	390	367	406	425	453	444
Depreciation expenses	1,969	3,081	5,035	4,392	3,974	3,385	3,030	2,627	5,679	4,786	4,327
Others	1,466	1,755	1,910	2,209	2,139	2,116	2,275	2,456	2,387	2,680	2,783
Total	18,183	19,935	21,861	21,445	20,907	20,527	19,709	21,215	25,482	25,398	25,955

Increase Rate



(%)

	FY03/16	FY03/17	FY03/18	FY03/19	FY03/20	FY03/21	FY03/22	FY03/23	FY03/24	FY03/25	Plan FY03/26
Materials	107.0	103.2	98.9	99.7	100.0	100.9	95.4	112.9	108.4	102.7	105.7
Personnel	99.9	97.1	98.3	97.0	99.8	105.6	99.8	106.0	105.7	103.9	101.9
Outsourcing	104.4	101.1	96.9	103.4	89.6	105.8	94.1	110.6	104.9	106.5	98.0
Depreciation expenses	143.7	156.4	163.4	87.2	90.5	85.2	89.5	86.7	216.1	84.3	90.4
Others	98.2	119.7	108.9	115.6	96.8	98.9	107.5	107.9	97.2	112.3	103.9
Total	108.4	109.6	109.7	98.1	97.5	98.2	96.0	107.6	120.1	99.7	102.2

Composition Rate

(%)

	FY03/16	FY03/17	FY03/18	FY03/19	FY03/20	FY03/21	FY03/22	FY03/23	FY03/24	FY03/25	Plan FY03/26
Materials	69.0	64.9	58.6	59.5	61.1	62.8	62.3	65.4	59.0	60.8	62.9
Personnel	9.9	8.7	7.8	7.7	7.9	8.5	8.9	8.7	7.7	8.0	8.0
Outsourcing	2.2	2.1	1.8	1.9	1.8	1.9	1.9	1.9	1.7	1.8	1.7
Depreciation expenses	10.8	15.5	23.0	20.5	19.0	16.5	15.4	12.4	22.3	18.8	16.7
Others	8.1	8.8	8.7	10.3	10.2	10.3	11.5	11.6	9.4	10.6	10.7
Total	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0	100.0



Reference] Sales by main products for the past 10 fiscal years(Consolidated)

Results by Quarter FY2014

	FY2014				FY2015				FY2016				FY2017				FY2018				FY2019			
	June 2014 Results		Sept. 2014 Results		Dec. 2014 Results		Mar. 2015 Results		June 2015 Results		Sept. 2015 Results		Dec. 2015 Results		Mar. 2016 Results		June 2016 Results		Sept. 2016 Results		Dec. 2016 Results		Mar. 2017 Results	
	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total
Kit products	4,425	52.7	4,750	53.7	5,000	53.8	4,701	54.0	4,719	54.6	5,043	56.0	5,288	56.2	5,207	54.7	5,135	56.7	5,286	57.1	5,458	57.6	5,243	57.8
Other non-woven products	2,473	29.4	2,538	28.7	2,650	28.5	2,348	27.0	2,414	27.9	2,440	27.1	2,499	26.6	2,373	24.9	2,369	26.2	2,359	25.5	2,416	25.5	2,261	24.9
Mekkin bag	638	7.6	677	7.7	699	7.5	653	7.5	651	7.5	656	7.3	694	7.4	695	7.3	664	7.3	681	7.4	683	7.2	635	7.0
Other nonwovens	341	4.1	350	4.0	406	4.4	352	4.1	349	4.0	343	3.8	371	3.9	352	3.7	343	3.8	340	3.7	372	3.9	333	3.7
New products	16	0.2	13	0.2	13	0.1	132	1.5	17	0.2	27	0.3	25	0.3	392	4.1	47	0.5	59	0.6	47	0.5	70	0.8
Others	482	5.7	491	5.6	507	5.5	482	5.5	474	5.5	483	5.4	504	5.4	472	5.0	477	5.3	509	5.5	484	5.1	494	5.5
Subsidiaries & other sales	20	0.2	15	0.2	18	0.2	30	0.3	12	0.1	18	0.2	18	0.2	19	0.2	17	0.2	17	0.2	19	0.2	27	0.3
Total	8,398	100.0	8,839	100.0	9,295	100.0	8,700	100.0	8,639	100.0	9,013	100.0	9,402	100.0	9,512	100.0	9,055	100.0	9,254	100.0	9,482	100.0	9,066	100.0

FY2017

	FY2017				FY2018				FY2019				FY2020				FY2021				FY2022			
	June 2017 Results		Sept. 2017 Results		Dec. 2017 Results		Mar. 2018 Results		June 2018 Results		Sept. 2018 Results		Dec. 2018 Results		Mar. 2019 Results		June 2019 Results		Sept. 2019 Results		Dec. 2019 Results		Mar. 2020 Results	
	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total
Kit products	5,299	57.9	5,408	58.4	5,645	58.2	5,139	58.5	5,339	59.0	5,462	59.5	5,785	59.5	5,242	60.3	5,481	60.7	5,683	60.8	5,953	61.5	5,366	58.5
Other non-woven products	2,312	25.2	2,298	24.8	2,442	25.2	2,133	24.3	2,248	24.8	2,219	24.2	2,384	24.5	2,036	23.4	2,146	23.7	2,205	23.6	2,241	23.2	2,085	22.7
Mekkin bag	664	7.3	666	7.2	703	7.3	599	6.8	620	6.9	647	7.0	671	6.9	602	6.9	632	7.0	638	6.8	642	6.6	616	6.7
Other nonwovens	334	3.7	326	3.5	362	3.7	308	3.5	311	3.4	308	3.4	346	3.6	292	3.4	292	3.2	299	3.2	322	3.3	606	6.6
New products	52	0.6	61	0.7	47	0.5	100	1.1	48	0.5	34	0.4	32	0.3	68	0.8	27	0.3	63	0.7	38	0.4	36	0.4
Others	474	5.2	488	5.3	473	4.9	482	5.5	464	5.1	494	5.4	478	4.9	432	5.0	433	4.8	433	4.6	458	4.7	424	4.6
Subsidiaries & other sales	21	0.2	17	0.2	23	0.2	28	0.3	21	0.2	18	0.2	24	0.3	21	0.2	23	0.3	17	0.2	22	0.2	35	0.4
Total	9,159	100.0	9,267	100.0	9,698	100.0	8,791	100.0	9,053	100.0	9,184	100.0	9,724	100.0	8,695	100.0	9,038	100.0	9,342	100.0	9,679	100.0	9,172	100.0

FY2020

	June 2020 Results		Sept. 2020 Results		Dec. 2020 Results		Mar. 2021 Results		June 2021 Results		Sept. 2021 Results		Dec. 2021 Results		Mar. 2022 Results		June 2022 Results		Sept. 2022 Results		Dec. 2022 Results		Mar. 2023 Results	
	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total
Kit products	4,786	57.1	5,407	57.8	5,855	58.8	5,138	58.3	5,418	60.9	5,505	61.0	6,163	62.4	5,470	61.0	5,906	62.5	5,867	60.2	6,382	61.8	6,008	63.6
Other non-woven products	2,063	24.6	2,432	26.0	2,528	25.4	2,259	25.6	2,053	23.1	2,031	22.5	2,222	22.5	1,923	21.5	2,006	21.2	2,085	21.4	2,068	20.0	1,853	19.6
Mekkin bag	592	7.1	600	6.4	649	6.5	559	6.4	577	6.5	616	6.8	640	6.5	618	6.9	634	6.7	663	6.8	677	6.6	605	6.4
Other nonwovens	429	5.1	452	4.8	428	4.3	369	4.2	368	4.1	385	4.3	313	3.2	428	4.8	383	4.1	604	6.2	660	6.4	461	4.9
New products	38	0.5	36	0.4	38	0.4	75	0.9	32	0.4	55	0.6	57	0.6	71	0.8	65	0.7	48	0.5	81	0.8	72	0.8
Others	447	5.3	411	4.4	446	4.5	394	4.5	420	4.7	419	4.6	464	4.7	432	4.8	433	4.6	463	4.8	439	4.2	435	4.6
Subsidiaries & other sales	19	0.2	16	0.2	15	0.2	10	0.1	24	0.3	17	0.2	21	0.2	21	0.2	17	0.2	20	0.2	24	0.2	10	0.1
Total	8,376	100.0	9,358	100.0	9,961	100.0	8,807	100.0	8,895	100.0	9,032	100.0	9,882	100.0	8,967	100.0	9,447	100.0	9,753	100.0	10,334	100.0	9,445	100.0

FY2023

	June 2023 Results		Sept. 2023 Results		Dec. 2023 Results		Mar. 2024 Results	
	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total
Kit products	6,339	65.5	6,361	64.5	6,673	65.3	6,128	65.6
Other non-woven products	1,893	19.6	1,899	19.3	1,964	19.2	1,695	18.1
Mekkin bag	625	6.5	620	6.3	683	6.7	608	6.5
Other nonwovens	310	3.2	477	4.8	357	3.5	357	3.8
New products	61	0.6	52	0.5	71	0.7	89	1.0
Others	429	4.4	430	4.4	446	4.4	455	4.9
Subsidiaries & other sales	19	0.2	14	0.2	21	0.2	10	0.1
Total	9,679	100.0	9,856	100.0	10,218	100.0	9,345	100.0

Results by period

	FY2014		FY2015		FY2016		FY2017		FY2018		FY2019		FY2020		FY2021		FY2022		FY2023	
	Fiscal 2014 Results		Fiscal 2015 Results		Fiscal 2016 Results		Fiscal 2017 Results		Fiscal 2018 Results		Fiscal 2019 Results		Fiscal 2020 Results		Fiscal 2021 Results		Fiscal 2022 Results		Fiscal 2023 Results	
	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total	Amount	% of total
Kit products	18,877	53.6	20,259	55.4	21,124	57.3	21,493	58.2	21,829	59.5	22,484	60.4	21,187	58.0	22,557	61.3	24,164	62.0	25,503	65.2
Other non-woven products	10,011	28.4	9,728	26.6	9,406	25.5	9,186	24.9	8,888	24.2	8,678	23.3	9,283	25.4	8,230	22.4	8,014	20.6	7,452	19.1
Mekkin bag	2,668	7.6	2,698	7.4	2,665	7.2	2,634	7.1	2,541	6.9	2,530	6.8	2,401	6.6	2,453	6.7	2,580	6.6	2,538	6.5
Other nonwovens	1,450	4.1	1,416	3.9	1,390	3.8	1,332	3.6	1,259	3.4	1,521	4.1	1,680	4.6	1,497	4.1	2,109	5.4	1,503	3.8
New products	177	0.5	463	1.3	224	0.6	261	0.7	184	0.5	166	0.4	190	0.5	216	0.6	266	0.7	274	0.7
Others	1,963	5.6	1,935	5.3	1,965	5.3	1,919	5.2	1,868	5.1	1,751	4.7	1,699	4.7	1,737	4.7	1,771	4.5	1,761	4.5
Subsidiaries & other sales	85	0.2	68	0.2	82	0.2	90	0.2	86	0.2	99	0.3	62	0.2	85	0.2	73	0.2	66	0.2
Total	35,233	100.0	36,568	100.0	36,859	100.0	36,918	100.0	36,658	100.0	37,232	100.0	36,504	100.0	36,778	100.0	38,981	100.0	39,100	100.0

Comparison of main Products and product grouping

main products	Product Grouping
Kit products	Surgical products
Non-woven products	Surgical products
Mekkin bag	Sterilization products
Other non-woven products	Surgical products
New products	Surgical products,Treatment products
Others	Sterilization products,Treatment products
Subsidiaries & other sales	Others